
Please try another search
Investing.com - Guggenheim raised its price target on Cidara Therapeutics (NASDAQ:CDTX) stock to $70.00 from $69.00 on Friday, while maintaining a Buy rating following the...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Belt Hold Bearish | 15 | Current | |||
Dark Cloud Cover | 15 | Current | |||
Doji Star Bearish | 1H | Current | |||
Harami Bearish | 1M | Current | |||
Harami Cross Bearish | 1M | Current | |||
Completed Patterns | |||||
Dark Cloud Cover | 5H | 1 | Aug 11, 2025 13:00 | ||
Three Outside Up | 1M | 2 | Jun 25 | ||
Advance Block Bearish | 1W | 2 | Jul 27, 2025 |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
VFD PLC | 12.10 | 12.50 | 12.10 | -1.30 | -9.70% | 25.79M | |||
Ellah Lakes | 14.60 | 14.60 | 13.80 | +1.32 | +9.94% | 32.33M | 14:34:59 | ||
Aiico | 3.85 | 3.85 | 3.80 | +0.35 | +10.00% | 154.73M | 14:34:59 | ||
Initiates | 13.20 | 13.20 | 12.10 | +1.20 | +10.00% | 9.58M | 14:34:59 | ||
BUA Cement | 168.60 | 168.60 | 168.60 | 0.00 | 0.00% | 783.47K | 14:34:59 | ||
Daarcomm | 1.03 | 1.03 | 0.95 | +0.06 | +6.19% | 12.00M | 14:34:59 | ||
Access Holdings | 27.70 | 27.70 | 27.50 | +0.10 | +0.36% | 28.76M | 14:34:59 | ||
Sterling Bank | 8.250 | 8.450 | 8.050 | -0.100 | -1.20% | 120.20M | 14:34:59 | ||
Linkassure | 2.26 | 2.26 | 2.08 | +0.20 | +9.71% | 703.59M | 14:34:59 | ||
Zenith Bank | 74.00 | 74.65 | 73.85 | -0.65 | -0.87% | 16.05M | 14:34:59 |
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review